Previous 10 | Next 10 |
2024-05-09 13:12:00 ET Clinical-stage biotech Editas Medicine (NASDAQ: EDIT) delivered quarterly results that fell well short of expectations on Wednesday. While one analyst trimmed her price target on the stock in response, she's still extremely bullish on its prospects. In fact, s...
2024-05-09 08:59:08 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global B...
2024-05-08 19:15:01 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for EDIT on May 8, 2024 06:25PM ET. The previous analyst recommendation was Underweight. EDIT was trading at $5.035 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-05-08 18:15:02 ET Citigroup analyst issues BUY recommendation for EDIT on May 8, 2024 04:01PM ET. The previous analyst recommendation was Buy. EDIT was trading at $5.035 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...
2024-05-08 10:57:01 ET Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Conference Call May 08, 2024, 08:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - ...
2024-05-08 10:44:36 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT) ...
2024-05-08 07:05:05 ET More on Editas Medicine Editas, Bristol Myers extend T cell therapy collaboration Read the full article on Seeking Alpha For further details see: Editas Medicine GAAP EPS of -$0.76 misses by $0.18, revenue of $1.14M misses by $6.16M
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-05-07 11:39:30 ET More on Editas Medicine Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript) Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript) Editas Medicine, Inc. (EDIT) ...
2024-05-05 08:00:00 ET As Wall Street embarks on the first full week of May, a diverse group of companies is set to report financial results. Notable names include The Walt Disney Company ( NYSE: DIS ), Palantir Technologies ( NYSE: PLTR ), Realty Income ( NYSE: ...
News, Short Squeeze, Breakout and More Instantly...
All patients treated in the RUBY trial are free of vaso-occlusive events post- renizgamglogene autogedtemcel (reni-cel) infusion Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal ...
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post- renizgamglogene autogedtemcel (reni-cel) infusion Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative con...